Multiple myeloma is characterized by extensive bone destruction with little or no new bone formation. A multiplicity of factors including receptor activator NF-jB (RANKL), macrophage inflammatory protein-1a, interleukin-3 and interleukin-6 can induce osteoclast formation in myeloma and drive the bone destructive process. Furthermore, factors are also produced either in the microenvironment or by myeloma cells themselves, which inhibit osteoblast differentiation and new bone formation. The combination of increased osteoclast formation with little or no bone repair in response to the previous bone destruction explains the severity of the bone disease in myeloma. Studies of the pathophysiology of myeloma bone disease have identified several novel therapeutic targets. These include antibodies to RANKL, chemokine receptor antagonists, which block the effects of chemokines on osteoclast differentiation and proteasome antagonists, which can affect both RANKL production and osteoprotegerin levels as well as inhibit osteoclast and enhance osteoblast differentiation. In addition, many of the new biologic agents being used for the treatment of patients with myeloma also further inhibit the bone destructive process. New therapies that can target both the tumor as well as the severe bone disease should be on the horizon to treat this devastating complication of myeloma.
Multiple myeloma is the most frequent cancer to metastasize to bone, with 80-90% of patients developing bone lesions. 1 The bone lesions are osteolytic and are associated with severe and debilitating bone pain, pathologic fractures, hypercalcemia and spinal cord compression syndromes. Approximately 45% of patients with myeloma will develop a fracture in the first year after diagnosis and 65% will develop a fracture over the course of their disease. 2 The bone destructive lesions can be extensive and severe resulting in loss of much larger amounts of bone than that which is seen in patients with osteoporosis. 3 Myeloma bone disease is distinct from bone disease caused by other types of tumors that are metastatic to bone in that although both myeloma and other osteolytic metastases induce increased osteoclastic bone resorption, osteoblast activity in myeloma is more severely decreased or even absent. 4 This explains the clinical finding that bone scans in patients with myeloma frequently underestimate the extent of bone disease. 5 Further, bone lesions in patients with myeloma rarely heal even when the patients are in complete remission. Thus, bone disease is one of the major sources of morbidity and even mortality in myeloma patients.
Any bone can be affected by myeloma bone disease, with the predominant sites of involvement occurring in the vertebral bodies and ribs. However, lesions can occur in phalanges and other unlikely sites, so that when patients present with pain in any particular skeletal area, one should look for a lytic lesion. Because of the intensive osteolytic activity in myeloma, therapies targeted at treating myeloma bone disease have focused on preventing osteoclastic bone destruction, since osteoclasts are responsible for the bone destruction and play a pivotal role in myeloma bone disease.
Osteolytic factors produced or induced by myeloma cells
The bone marrow microenvironment plays a critical role in the development of myeloma bone disease. Factors produced by myeloma cells or by marrow stromal cells and T cells in the marrow microenvironment in response to myeloma cells are all involved in the increased bone resorptive process. Further, growth factors released by the bone resorptive process can increase tumor burden in myeloma patients. Recent studies have identified several important factors involved in myeloma bone disease. These include receptor activator NF-kB (RANKL), osteoprotegerin (OPG), macrophage inflammatory protein-1a (MIP-1a) and interleukin (IL)-3. In addition, IL-6, which is a growth factor and anti-apoptotic factor for myeloma cells, can also induce osteoclast formation, but its role in myeloma bone disease is still unclear. 6 Receptor activator of NF-kB ligand in myeloma Normal bone physiology involves complex interactions between osteoblasts and osteoclasts. Osteoblasts are the bone-forming cells, which deposit bone matrix, and osteoclasts mediate bone resorption. Normally, bone resorption and bone formation are tightly regulated and are balanced, but in myeloma, the normal balance between osteoclastic bone resorption and bone formation is severely deregulated. The RANK/RANKL signaling pathway is a primary mediator of osteoclastic-induced bone resorption and a critical element in the bone remodeling process. RANK is a transmembrane signaling receptor, which is a member of the tumor necrosis receptor superfamily, and is expressed on the surface of osteoclast precursors. 7, 8 RANKL's expression on the surface of osteoblasts and stromal cells is increased by most hormones and cytokines that stimulates bone resorption. 9 The interaction between RANKL and its receptor RANK induces osteoclast formation, increases osteoclastic bone resorption and enhances osteoclast survival. OPG is a soluble decoy receptor for RANKL and is a member of the TNF receptor superfamily. 10 OPG is produced by osteoblasts and blocks the interaction of RANKL with RANK, and thereby limits osteoclastogenesis. Normally, the ratio of RANKL to OPG is strongly in favor of OPG, with extremely low levels of RANKL expression. The important role for RANKL in normal osteoclastogenesis has been shown in studies using mouse functional genomics, which demonstrated that the absence of either RANKL or RANK results in severe osteoperosis while the absence of OPG causes severe osteopenia and spontaneous fractures in mice. [10] [11] [12] [13] [14] In myeloma, RANKL expression in the marrow microenvironment is markedly increased, and the increased ratio of RANKL to OPG appears to be a major mediator of myeloma bone disease. Other cell sources for RANKL in addition to osteoblasts in myeloma include T lymphocytes 15 as well as myeloma cells themselves, which have been reported to express low levels of RANKL. [16] [17] [18] [19] Pearse and co-workers 20 were the first to clearly demonstrate that RANKL expression was upregulated in bone marrow biopsies in patients with myeloma while OPG was decreased. They detected RANKL expression in cells in the marrow microenvironment rather than the myeloma cells. The reduction in OPG has been reported to be due in part to binding to CD138, syndecan-1, which is expressed on myeloma cells. The OPG-CD138 complex is then internalized and OPG is degraded by myeloma cells. 21 Giuliani and co-workers 15 have shown that circulating levels of OPG and RANKL in patients correlate with clinical activity of myeloma, including bone disease. An elevated ratio of RANKL to OPG was associated with severe bone disease as well as an extremely poor prognosis. 22 Further, murine models of myeloma demonstrated that inhibition of RANKL can prevent bone destruction in either the SCID-hu model and the T2 syngeneic model. 23, 24 These studies have shown that blocking RANKL, either with a soluble form of the RANK receptor or with OPG, decreases bone destruction as well as tumor burden. These data suggest that inhibiting osteoclastic bone destruction results in an antimyeloma effect. This 'vicious cycle' of bone destruction and tumor growth has been reported in other metastatic cancers to bone including breast cancer, prostate cancer, as well as myeloma. 1 The basis for the decreased tumor burden that occurs in preclinical models of myeloma when bone destruction is inhibited is still unclear, but most likely reflects the loss of growth factors released from the bone microenvironment by osteoclastic bone resorption. In addition, several groups reported that osteoclasts can support the growth of myeloma cells through production of both IL-6 and osteopontin 25, 26 suggesting that decreases in osteoclast formation should impede the growth of myeloma cells.
Macrophage inflammatory protein-1a
Approximately 70% of patients with myeloma have increased levels of MIP-1a in their bone marrow at both the mRNA and protein levels. 27 In contrast, MIP-1a levels are only slightly increased in other hematologic malignancies except for T cell leukemia -lymphoma, which is also associated with hypercalcemia in the majority of patients. 28 MIP-1a is an extremely potent inducer of human osteoclast formation, and can induce osteoclast formation in vitro at concentrations of 10-100 pg/ml. Levels of MIP-1a in marrow of patients with myeloma range between 100 and 2000 pg/ml. 27 Similarly, Hashimoto and co-workers 29 have shown that elevated levels of MIP-1a and MIP-1b are both detectable in patients with myeloma, and that high levels of MIP-1a are associated with an extremely poor prognosis. Most recently, Magrangeas and co-workers 30 have shown by gene-expression profiling that MIP-1a expression is the gene most highly correlated with bone destruction in myeloma patients. Further, in vivo studies, using murine models of myeloma bone disease, have demonstrated that MIP-1a can induce osteoclast formation and bone destruction and that blocking MIP-1a expression in myeloma cells injected into SCID mice results in decreased tumor burden and bone destruction. 27 In addition to inducing osteoclast formation, MIP-1a can enhance the effects of RANKL and IL-6 on osteoclast formation. Oyajobi and co-workers 31, 32 have reported using the 5TGM1 murine myeloma model that blocking MIP-1a activity with a neutralizing antibody to MIP-1a also blocked bone destruction and decreased tumor burden.
In addition to its role in osteoclast formation, MIP-1a also increases adhesive interactions between myeloma cells and marrow stromal cells. 27 When myeloma cells come to the bone marrow, they bind to marrow stromal cells through adhesive interactions involving a 4 b 1 or a 5 b 1 integrin and VCAM-1. This results in increased production of RANKL, IL-6, vascular endothelial growth factor (VEGF) and tumor necrosis factor-a by marrow stromal cells. These factors then lead to enhanced myeloma growth, increased bone destruction and angiogenesis. Recently, Masih-Khan and co-workers 33 demonstrated that patients with a t4;14 chromosome translocation, which results in a constitutively active FGFR3 receptor activity, produce high levels of MIP-1a and that MIP-1a is the downstream target of FGFR3 signaling. Patients with a t4;14 chromosomal translocation have a very poor prognosis, which may reflect the increased MIP-1a production.
IL-3
In addition to RANKL and MIP-1a, myeloma patients have also been found to have elevated levels of IL-3 in their marrow plasma. 34 Approximately 75% of bone marrow samples from patients with myeloma have elevated IL-3 protein levels, and IL-3 is both a growth factor for myeloma cells as well as a potent stimulator of osteoclast formation. 34 IL-3 can also enhance the effects of RANKL and MIP-1a and stimulate the growth of IL-6 dependent myeloma cells. Further, inhibiting IL-3 activity in marrow plasma samples from patients with myeloma blocks the capacity of the marrow plasma to induce human osteoclast formation in vitro.
IL-6
IL-6 is a potent inducer of human osteoclast formation. 35 IL-6 levels are increased in patients with myeloma and patients with monoclonal gammopathy of undetermined significance (MGUS). 36 Bone marrow levels of IL-6 have been correlated with bone turnover markers. 37 IL-6 can increase the effects of MIP-1a, IL-3 and RANKL on osteoclast formation in murine systems and can also induce RANKL expression by murine marrow stromal cells. However, the precise role that IL-6 plays in osteoclast formation and myeloma tumor burden remains to be defined. Recent studies have suggested that blocking IL-6 may decrease the growth of myeloma cells in patients. 38 
p38 MAP kinase
When myeloma cells bind to marrow stromal cells, these adhesive interactions result in increased signaling of NF-kB and p38 MAP kinase. p38 MAP kinase is involved in both osteoclastic growth and differentiation as well as induction of RANKL expression in osteoblasts. Nguyen et al. 39 have shown that blocking p38 MAP kinase signaling with a highly specific antagonist inhibits both IL-6 production, VEGF production and adhesion of myeloma cells to marrow stromal cells. These authors further showed that inhibiting p38 MAP kinase dose-dependently decreased osteoclast formation in human marrow cultures. Vanderkerken and co-workers 40 have recently reported that inhibiting p38 MAP kinase in the 5T2 murine model of myeloma decreases tumor burden, prevents the development of myeloma bone disease and increases survival of these mice. Thus targeting this pathway may have therapeutic benefits for patients with myeloma.
p62 (sequestosome-1)
p62 is a recently identified member of the NF-kB signaling pathway, which is involved in IL-1, TNF and RANKLmediated NF-kB activation. p62 forms a complex with TRAF6, TRAF2 and atypical protein kinases z or l to enhance NF-kB signaling. Because NF-kB is upregulated in the marrow microenvironment in patients with myeloma, Kurihara and co-workers 41 have examined the role of p62 in myeloma bone disease. These investigators recently reported that deleting p62 in marrow stromal cells, using mouse genomic techniques, decreases the capacity of these marrow stromal cells to support osteoclast formation, myeloma cell growth and to produce RANKL and TNF-a. They further found that TNF-a could reverse the effects of loss of p62 in cocultures of myeloma cells with marrow stromal cells, through upregulation of VCAM-1.
Osteoblasts in myeloma
As noted above, osteoblast activity is markedly suppressed in advanced stages of myeloma, with absent or apoptotic osteoblast being found frequently. 42 However, the role that osteoblasts play in the bone destructive process and the growth of myeloma cells is just beginning to be defined. Yaccoby and co-workers 43 have reported that osteoblasts, in contrast to osteoclasts, suppress the growth of myeloma cells. Several factors have been identified, which may mediate the osteoblast suppression in myeloma. These include IL-3, dickkopf-1 (DKK1), secreted frizzled-related proteins-2 or 3 (Secreted frizzled-related proteins (sFRP)-2 or sFRP-3) and IL-7.
44-47 DKK1, sFRP-2 and sFRP-3 inhibit the Wnt signaling pathway, which plays a critical role in osteoblast differentiation. Soluble inhibitors of the Wnt signaling pathway affect osteoblast differentiation but not osteoblast survival.
IL-3
IL-3 is a potent inducer of human osteoclast formation and the growth of myeloma cells. Ehrlich and co-workers 44 reported that IL-3 also can inhibit osteoblast differentiation by both mouse and human osteoblast progenitors. They further showed that osteoblast differentiation was inhibited by marrow plasma that had high levels of IL-3 in patients with myeloma and that this could be reversed by addition of a neutralizing antibody to IL-3. These workers further showed that the effects of IL-3 on osteoblast differentiation were indirect and appeared to be mediated through monocyte macrophages present in the marrow microenvironment. These results suggest IL-3 plays a dual role in the bone destructive process in myeloma, through directly stimulating osteoclast formation, enhancing the effects of RANKL and MIP-1a and indirectly inhibiting osteoblast formation. In addition, IL-3 can serve as a growth factor for myeloma cells further increasing the bone destructive process.
DKK1
DKK1 is a soluble inhibitor of the Wnt signaling pathway that is produced by osteoblasts and plays a critical role in osteoblast suppression in myeloma. 47 Tian and co-workers 47 reported that DKK1 is produced by myeloma cells, and that gene expression profiling studies showed that levels of DKK1 mRNA correlated with bone lesions in patients with myeloma. However, other investigators have not detected production of DKK1 by myeloma cells and have shown that DKK1 is produced by the marrow microenvironment in myeloma. 48 Giuliani and co-workers 48 found that 74% of myeloma patients expressed DKK1. They also reported that significantly higher levels of DKK1 were detected in myeloma patients compared to patients with MGUS. Myeloma patients with osteolytic lesions had significantly higher bone marrow levels of DKK1 than those without osteolytic lesions. Recently, Yaccoby and co-workers 49 have shown in the SCID-rab model of myeloma, in which a juvenile rabbit bone is implanted in a SCID mouse and the rabbit bone injected with primary myeloma cells, that an antibody to DKK1 blocked the bone destructive process, increased bone formation and decreased tumor burden. The DKK1 antibody also increased bone formation in the bones of the host as well. Thus blocking DKK1 can affect both the growth of myeloma cells, improve bone formation and decrease bone destruction.
Secreted frizzled-related proteins
sFRP-2 and sFRP-3 have both been reported to be increased in patients with myeloma. These factors are inhibitors of the Wnt signaling pathway involved in osteoblast differentiation. Oshima and co-workers 46 have shown that myeloma cell lines and primary myeloma cells suppress murine osteoblast differentiation, and this is reversed by inhibiting sFRP-2. Giuliani and co-workers 48 failed to detect sFRP-2 in samples from myeloma patients, but instead found sFRP-3. These workers showed that sFRP-3 was produced by the marrow microenvironment rather than myeloma cells. Thus at least three Wnt signaling inhibitors have been detected in myeloma, DKK1, sFRP-2 and sFRP-3, which can inhibit osteoblast differentiation and suppress bone formation.
IL-7
In addition to increased levels of IL-3, Giuliani and coworkers 45 have also found increased levels of IL-7 in marrow plasma samples from patients with myeloma. They showed that IL-7 is a potent inhibitor of osteoblast differentiation. IL-7 also can affect osteoclast formation both positively and negatively. 45, 50, 51 Anti-IL-7 reversed the inhibition of human osteoblast differentiation by myeloma cell lines and primary myeloma cells and could also inhibit in vitro bone nodule formation by osteoblast precursors by blocking the effects of a key transcription factor critical for osteoblast differentiation, cbfa1. 45 Therapeutic options for myeloma bone disease As reviewed above, multiple factors stimulate osteoclast formation and inhibit osteoblast differentiation in myeloma. However, the key cell responsible for the bone destructive process is the osteoclast, and therapies that inhibit osteoclast formation or osteoclast activity have a profound effect on myeloma bone disease. The bisphosphonates (pamidronate, zoledronic acid and ibandronate) inhibit osteoclast formation and induce osteoclast apoptosis. Berenson and co-workers were the first to demonstrate that bisphosphonates, given intravenously, had a major effect on myeloma bone disease. These investigators showed that administration of pamidronate at 90 mg every 3-4 weeks reduced skeletal-related events including fractures, hypercalcemia, surgery to bone and radiation to bone by almost 50% over the first 9 months of the study, and there was a significant benefit to skeletal-related events for up to 21 months of the study. 52 Similarly, Coleman and coworkers 53 have shown that zoledronic acid can decrease bone resorption markers in patients with myeloma, and that zoledronic acid at 4 mg i.v. every 3-4 weeks was as effective as pamidronate in decreasing skeletal-related events in myeloma patients. 54 However, bisphosphonates only decreased skeletal-related events by 50%, and patients still continued to have skeletal-related events albeit at a much lower rate. In addition, bisphosphonate therapies are associated with renal toxicity as well as osteonecrosis of the jaw. 55 Osteonecrosis of the jaw occurs in about 4-6% of patients with myeloma treated with intravenous bisphosphonates, and the incidence of osteonecrosis of the jaw has been reported to increase with the use of the more potent bisphosphonates and prolonged use of the drugs. However, the mechanisms responsible or whether there is a causeand-effect relationship between osteonecrosis of the jaw and bisphosphonate therapy remains to be determined. Currently, many questions surround how long to administer bisphosphonates to patients with myeloma after the first 9-12 months, and several groups have developed guidelines for the use of bisphosphonates in myeloma. 56 A randomized prospective trial of zoledronic acid in patients with myeloma in which patients are treated with zoledronic acid at standard schedule for 9-12 months, and then are either treated monthly or every 3 months with bisphosphonates, is currently ongoing. This trial should determine the safety, efficacy and toxicity of zoledronic acid given in this manner.
Denosumab
RANKL plays a critical role in osteoclast formation and osteoclast survival and is a central factor in the osteoclastic bone destruction in myeloma. Recently, a humanized monoclonal antibody to RANKL has been developed. Denosumab can reduce bone resorption markers rapidly in patients with myeloma and the reduction persists for up to 90 days. 57 The antibody is highly specific for RANKL, does not bind other members of the TNF supergene family and is currently in clinical trial in myeloma and other disease processes associated with osteoclastic bone destruction. Targeting the RANKL/OPG pathway should have a major impact on myeloma bone disease. Phase I studies have also been done with recombinant OPG in patients with myeloma. 58 A single dose of recombinant OPG decreased bone resorption markers for up to a month when given intravenously in an analogous fashion to pamidronate. However, because of concerns of developing antibodies to OPG, this drug has not been brought further into clinical development.
Other novel therapies for myeloma bone disease
Inhibition of p38 MAP kinase signaling pathway can have a profound effect on osteoclast formation. 59, 60 A phase II clinical trial was recently completed using a highly specific p38 MAP kinase inhibitor, SCIO-469 either alone or in combination with bortezomib. The results of this trial are not yet available.
Bortezomib, a proteasome antagonist, appears to be a potentially important agent in treating myeloma bone disease in addition to its anti-myeloma effects. Several groups have shown that patients receiving bortezomib have increased serum levels of bone formation markers. 61, 62 However, it is unclear if bortezomib is increasing bone formation at sites involved with myeloma or sites that are not involved with myeloma in these patients. Garrett and co-workers 63 have shown that proteasome antagonists can enhance bone formation in preclinical models through increased production of bone morphogenic protein-2, a potent stimulator of osteoblast differentiation. Further, Terpos and co-workers 64 have reported that patients receiving bortezomib have decreased serum levels of RANKL and increased levels of OPG, consistent with an effect on bone formation, but they did not find healing of lytic lesions in these patients. Recently, Giuliani et al. 65 have reported increased osteoblast activity in marrow biopsies from myeloma patients who respond to bortezomib. Future studies will determine whether proteasome antagonists, in addition to being anti-myeloma drugs, can also enhance bone formation in myeloma patients.
MIP-1a is an important inducer of human osteoclast formation and is increased in patients with myeloma. Oba and co-workers 66 reported that MIP-1a induces osteoclast formation via the CCR1 chemokine receptor and can upregulate RANKL expression using CCR5 chemokine receptor in marrow stromal cells. Blocking either CCR1 or CCR5 inhibits the effects of MIP-1a on osteoclast formation. In addition, myeloma cells express the CCR1 receptor, and Lentzsch and co-workers 67 have shown that MIP-1a can enhance the growth of myeloma cells through signaling through CCR1. Thus CCR1 antagonists are promising agents for treating both myeloma and myeloma bone disease. It is anticipated that in the next several years clinical trails will be undertaken using CCR1 antagonists.
As noted above, blocking DKK1 in preclinical models with a neutralizing antibody blocks bone destruction and increases bone formation of myeloma. However, it is unclear if blocking DKK1 can enhance bone formation in lytic lesions in patients with myeloma since the mechanisms responsible for the inability of myeloma bone lesions to heal, even when myeloma is in complete remission, are unknown. It is possible that there may not be sufficient mesenchymal stem cells to differentiate to osteoblasts or that the myeloma bone lesion is inhospitable to osteoblast differentiation. Thus factors which can enhance osteoblast growth may have no effect on myeloma. A bone anabolic agent, parathyroid hormone (PTH), has been used in preclinical models of myeloma to stimulate bone growth. Pennisi 68 has shown that PTH can increase bone density by 20% in SCID-rab mice engrafted with human myeloma cells and that this increase in bone mineral density inhibits myeloma cell growth. However, there is a concern that stimulating osteoblast formation in myelomatous lesions could enhance production of growth factors that increase Tumor-derived osteoblast inhibitory factors:
Bisphosphonates Bone (+) Figure 1 Treatment strategies for myeloma bone disease. In addition to bisphosphonates, which inhibit osteoclast bone resorption, several new potential therapies for treating myeloma bone disease have recently been identified. These include denosumab, an antibody to RANKL, anti-dickkopf-1 (DKK1) and bortezomib. Bortezomib lowers the levels of DKK1 and RANKL while increasing osteoblast activity. In addition, chemokine receptor antagonists such as the CCR1 antagonist, which block the effects of MIP-1a, are also under consideration. Potential therapies are shown in parentheses next to their target. tumor burden. However, this does not appear to be the case in this preclinical model of myeloma. Clinical trials of bone anabolic agents in myeloma have not been reported to date, although most likely they will be done in patients who already received bisphosphonates or currently are receiving bisphosphonates and chemotherapeutic or biologic treatments including bortezomib. Since bisphosphonates may blunt the effects of PTH, the anabolic potential of PTH in myeloma is unclear.
Other agents in clinical trial for myeloma also have effects on osteoclasts. Feng and co-workers 69 have reported that an NF-kB antagonist, SDX-308, can inhibit the growth of myeloma cells and osteoclast formation in human marrow cultures. They further found that IMID drugs such as revlimid or thalidomide can also inhibit osteoclast formation by blocking differentiation of osteoclast precursors to osteoclasts. 70 Bortezomib and other proteasome antagonists can also inhibit osteoclast formation in vitro by inhibiting NF-kB signaling. Thus many of the agents now being tested for treating myeloma also may affect the myeloma microenvironment and inhibit osteoclast formation and may enhance osteoblast differentiation.
Summary
Multiple myeloma is characterized by extensive bone destruction with little or no new bone formation. A multiplicity of factors including RANKL, MIP-1a, IL-3 and IL-6 can induce osteoclast formation in myeloma and drive the bone destructive process. Furthermore, multiple factors are also produced either in the microenvironment or by myeloma cells themselves, which inhibit osteoblast differentiation and new bone formation. The combination of increased osteoclast formation with little or no bone repair in response to the previous bone destruction, explains the severity of the bone disease in patients with myeloma. Studies of the pathophysiology of myeloma bone disease have identified several novel targets for treating patients with this debilitating complication of cancer ( Figure 1 ). These include antibodies to RANKL, chemokine receptor antagonists, which block the effects of chemokines on osteoclast differentiation, and proteasome antagonists, which can affect both RANKL production and OPG levels as well as inhibit osteoclast and enhance osteoblast differentiation. Many of the new biologic agents being tested for the treatment of patients with myeloma also have significant effects on the bone microenvironment, and further inhibit the bone destructive process. Multiple new therapies that can target both the tumor as well as the severe bone disease should be on the horizon to treat this devastating complication of myeloma.
